No Picture
Trading Ideas

‘The data is going to get worse from here’: Chief Strategist on economic data in response to the coronavirus

Emily Roland, John Hancock Investment Management Co-Chief Investment Strategist, addresses how U.S. markets have their worst quarter since the 2008 recession and how long it could take for a recovery. Roland joins Yahoo Finance’s On The Move to discuss. …read more […]

No Picture
Trading Ideas

Oil’s Crash Tips Former Titan of U.S. Shale Into Bankruptcy

(Bloomberg) — The unprecedented collapse in global oil markets brought another driller to its knees, forcing a champion of what was once the premier U.S. shale field to seek protection from creditors.Whiting Petroleum Corp., facing more than a quarter-billion dollar debt maturity, filed for bankruptcy Wednesday, perhaps the most illustrious of the shale explorers thus far humbled by an unforgiving rout in every corner of the oil business.American crude has surrendered two-thirds of its value this year and just closed out its worst-ever quarterly performance. As many as 70% of the nation’s 6,000 oil explorers eventually may go under, according …read more […]

No Picture
Trading Ideas

Moderna Hopeful of Phase 1 Data for COVID-19 Vaccine by Summer, Analyst Reiterates Buy

The images of eerie empty streets, along with the sight of masked civilians roaming around, all add to the sense that we are currently on the set of a dystopian sci-fi movie. Add into the mix the race among pharmaceutical companies to develop a COVID-19 vaccine or treatment, and the drama is further enhanced. But as we all know, this is no screenplay, but current daily life around the globe. Vying for a starring role in this real-life drama is biotech Moderna (MRNA). The messenger RNA specialist is developing mRNA-1273, a vaccine against COVID-19 currently in Phase 1 testing, and …read more […]

No Picture
Trading Ideas

Judge’s Record Looks Unpromising for Amarin’s Appeal; Analyst Remains Bullish

It hasn’t been a good week for biotech Amarin (AMRN). On Monday, a District of Nevada judge ruled against the company and in favor of two generic drug makers seeking to establish their own versions of Amarin’s treatment for high triglycerides, Vascepa, thereby, making mincemeat of Amarin’s six patent claims. Judge Du’s ruling caught the Street somewhat by surprise, as it was widely expected Amarin would prevail in the case. Alas, investors were not impressed and on Tuesday, the stock was sent tumbling by a merciless 70%. The next step, naturally, involves an appeal. With this in mind, H.C. Wainwright’s …read more […]

No Picture
Trading Ideas

3 “Strong Buy” Dividend Stocks Yielding At Least 10%

The financial markets shifted into bear territory weeks ago, seeing the worst stock losses since the Great Depression. It’s clear now that the coronavirus pandemic has pushed us into recession; the unanswered question is, how long will it be? For now, though, we have a record to ponder: this has been the worst first quarter for US stocks since record keeping began.Last week, however, the major indexes have showed some gains. Investors are uncertain if this marks a true turnaround, or just a short-lived rally in a larger bear market. The consensus seems to be toward the latter. Jeffrey Solomon, …read more […]